연구발표논문

2013/05/11

Hiroyuki Abe, Touko Shimamoto, Shinichiro Akiyama and Minako Abe
Abe Cancer Clinic, Japan

1. Introduction

The unpredictability of efficacy and toxicity of treatment are limitations of current standard cancer treatments. The clinical results

obtained by standard therapies suggest a need for a paradigm change in cancer treatment. In recent years, immune cell therapy

has been in the spotlight with the expectation of opening the door to a new area of cancer therapy. Targeted cancer therapy,

which selectively takes action against targets expressed in the tumor surface, seems to be promising.

The immune system can control various types of tumors. Antigen-non-specific innate immunity and antigen-specific adaptive

immunity can reject tumors.

The identification of tumor antigens recognized by T cells has facilitated the development of immune cell therapy in clinical

oncology. The dendritic cell based cancer vaccine aims to induce tumor specific effector T cells (cytotoxic T lymphocyte, CTL)

that can reduce tumor mass as well as tumor specific memory T cells that can control tumor relapse.

In this text, immune cell target therapy in clinical oncology will be discussed and hopefully this will be helpful in daily clinical

practice.

• 암치료 교과서- Conventional and Innovative Approaches

INTECH, May 2013, Chapter 14